A preventive treatment has finally arrived that could change the life of many migraine sufferers. Around 2 percent of the global population experiences chronic migraine, which puts the condition among the top 10 causes of disability in the world. The new drug, Aimovig, is intended to help sufferers block the calcitonin gene-related peptide (CGRP) fragments from infusing the brain.